Published in Pharmacol Biochem Behav on November 04, 2010
Anti-obesity drugs: past, present and future. Dis Model Mech (2012) 1.36
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol (2012) 1.32
2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. J Med Chem (2014) 1.05
Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol (2011) 1.05
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther (2013) 0.97
Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol (2012) 0.96
The endocannabinoid system: directing eating behavior and macronutrient metabolism. Front Psychol (2015) 0.89
Effect of the novel polysaccharide PolyGlycopleX® on short-chain fatty acid production in a computer-controlled in vitro model of the human large intestine. Nutrients (2014) 0.83
Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology (Berl) (2012) 0.81
Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.79
Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. Behav Pharmacol (2015) 0.76
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. Int J Neuropsychopharmacol (2016) 0.75
Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice. Braz J Med Biol Res (2017) 0.75
A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med (2005) 5.38
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 3.62
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol (2002) 3.33
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 2.52
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci (1998) 2.12
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) (2007) 1.85
Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci (2004) 1.79
Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) (2003) 1.61
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J (2005) 1.56
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) (2005) 1.52
Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) (2008) 1.51
Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids (2002) 1.48
Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol (2006) 1.46
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology (2007) 1.44
Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes (2008) 1.39
Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol (2003) 1.38
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology (2008) 1.23
Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther (2005) 1.15
A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol (2007) 1.15
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int (2007) 1.14
Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. Anal Chem (2007) 1.13
CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev (2007) 1.09
Endogenous cannabinoids and appetite. Nutr Res Rev (2001) 1.09
Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res (2010) 1.08
Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) (2009) 1.04
Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes (2006) 0.99
The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res (2009) 0.97
The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav (2006) 0.97
The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes (Lond) (2006) 0.95
CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab (2007) 0.94
Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology (Berl) (2006) 0.94
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav (2010) 0.92
Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes (Lond) (2008) 0.89
AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. Br J Pharmacol (2006) 0.89
Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest (2006) 0.86
Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition. Int J Obes (Lond) (2009) 0.84
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. J Neurochem (2009) 0.84
Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. Eur J Pharmacol (2007) 0.83
The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action? Int J Obes (Lond) (2006) 0.81
Effect of flavour of liquid Ensure diet supplement on energy intake in male SD rats. Physiol Behav (2006) 0.80
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology (2004) 4.04
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology (2012) 2.11
Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest (2007) 2.09
Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat Med (2012) 2.08
Inflammatory neuropathies of the enteric nervous system. Gastroenterology (2004) 2.02
Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr (2009) 1.90
Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther (2010) 1.81
Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology (2010) 1.80
Gastric bypass increases energy expenditure in rats. Gastroenterology (2009) 1.79
Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol (2003) 1.78
All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev (2012) 1.74
Enhanced excitability of myenteric AH neurones in the inflamed guinea-pig distal colon. J Physiol (2003) 1.65
Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes (2013) 1.64
Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. Gastroenterology (2011) 1.64
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci U S A (2008) 1.55
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
Purinergic neuron-to-glia signaling in the enteric nervous system. Gastroenterology (2009) 1.48
Dairy protein attenuates weight gain in obese rats better than whey or casein alone. Obesity (Silver Spring) (2009) 1.47
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
Novel functional roles for enteric glia in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2012) 1.44
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology (2007) 1.44
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs (2009) 1.42
CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol (2003) 1.39
Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats. Br J Nutr (2011) 1.36
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis (2009) 1.35
Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol (2004) 1.33
Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol (2003) 1.32
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci (2008) 1.30
Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. Am J Physiol Gastrointest Liver Physiol (2004) 1.29
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol (2011) 1.27
Cannabinergic ligands. Chem Phys Lipids (2002) 1.25
Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat (2009) 1.25
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 1.24
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol (2008) 1.22
Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. Auton Neurosci (2006) 1.21
Cyclooxygenase-2 contributes to dysmotility and enhanced excitability of myenteric AH neurones in the inflamed guinea pig distal colon. J Physiol (2004) 1.20
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther (2003) 1.20
Role of enteric glia in intestinal physiology: effects of the gliotoxin fluorocitrate on motor and secretory function. Am J Physiol Gastrointest Liver Physiol (2006) 1.19
Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. J Med Chem (2013) 1.19
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl) (2008) 1.19
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem (2007) 1.19
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol (2008) 1.18
The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol (2007) 1.17
Dietary supplementation of high-performance Canadian athletes by age and gender. Clin J Sport Med (2007) 1.17
Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol (2007) 1.16
Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol (2004) 1.16
Inducible nitric oxide synthase from bone marrow-derived cells plays a critical role in regulating colonic inflammation. Gastroenterology (2007) 1.16
Influence of performance level on dietary supplementation in elite Canadian athletes. Med Sci Sports Exerc (2006) 1.16
Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology (Berl) (2005) 1.16
Synaptic facilitation and enhanced neuronal excitability in the submucosal plexus during experimental colitis in guinea-pig. J Physiol (2005) 1.15
A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol (2007) 1.15
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Cannabinoid receptors as therapeutic targets. Curr Pharm Des (2006) 1.13
Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. Anal Chem (2007) 1.13
Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav (2007) 1.13
Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain. J Physiol (2004) 1.13
Purinergic neuromuscular transmission is selectively attenuated in ulcerated regions of inflamed guinea pig distal colon. J Physiol (2010) 1.12
Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys Lipids (2002) 1.12
Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol Behav (2004) 1.12
Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. PLoS One (2012) 1.11
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther (2008) 1.10
Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem (2005) 1.09
Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology (2005) 1.09
Persistent alterations to enteric neural signaling in the guinea pig colon following the resolution of colitis. Am J Physiol Gastrointest Liver Physiol (2006) 1.09
Emerging roles for enteric glia in gastrointestinal disorders. J Clin Invest (2015) 1.08
Enteric glia are targets of the sympathetic innervation of the myenteric plexus in the guinea pig distal colon. J Neurosci (2010) 1.08
High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. J Med Chem (2005) 1.08
Synaptic plasticity in myenteric neurons of the guinea-pig distal colon: presynaptic mechanisms of inflammation-induced synaptic facilitation. J Physiol (2007) 1.08
Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res (2010) 1.08
Dextran sodium sulfate-induced colitis reveals nicotinic modulation of ion transport via iNOS-derived NO. Am J Physiol Gastrointest Liver Physiol (2004) 1.07
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis (2010) 1.07
Ectonucleotidases in the digestive system: focus on NTPDase3 localization. Am J Physiol Gastrointest Liver Physiol (2011) 1.07
CB1 cannabinoid receptor ligands. Mini Rev Med Chem (2005) 1.06
Nitric oxide regulation of colonic epithelial ion transport: a novel role for enteric glia in the myenteric plexus. J Physiol (2011) 1.06
Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Mol Reprod Dev (2002) 1.06
Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. J Proteome Res (2008) 1.06
Area postrema neurons are modulated by the adipocyte hormone adiponectin. J Neurosci (2006) 1.06
Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin Chem Lab Med (2008) 1.06
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 1.05
Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats. Endocrinology (2013) 1.05
The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J Biol Chem (2005) 1.05
Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitro. Nutrition (2008) 1.04
Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacol Biochem Behav (2005) 1.04